1. Age from 18 to 75 years (including boundary values);
2. Diagnosed with histologically and cellularly confirmed cancer of lung, breast, pancreas, ovary, or colon;
3. At least 8 weeks since any prior systemic therapy to treat the underlying malignancy (standard or investigational);
4. Life expectancy \> 6 months, and performance status（KPS）\> 60 points;
5. Organ functions meet the following criteria:
1. Blood bilirubin \< 2mg/dL,
2. Aspartate transaminase（AST）\<100 IU/L,
3. Alanine transaminase（ALT） \<100 IU/L,
4. Creatinine \<1.5 mg/dL,
5. Urea nitrogen ≤ 25 mg/dL,
6. Hemoglobin ≥ 9.0 g/dL,
7. White blood cell count\>3.5×109/L,
8. Neutrophil count \>1.5x109/L,
9. Platelet count \> 80 × 109 /L,
10. Hematocrit \>0.20,
6. No severe infections.
You may not be if
1. Subjects who take combined systemic steroids within 2 weeks prior to treatment (except inhaled steroids);
2. Patients who take chemotherapy within 1 month prior to treatment;
3. Subjects receiving drugs that stimulate the production of bone marrow hematopoietic cells within two weeks prior to treatment;
4. Patients with T lymphoma and NK cell lymphoma;
5. Patients with autoimmune diseases, including but not limited to lupus erythematosus, rheumatoid arthritis, etc.;
6. Seriously uncontrollable infected patients;
7. Patients who are allergic to the biological agents in this treatment;
8. Patients with organ transplantation or organ failure;
9. Subjects with severe cardiovascular disease and severe renal failure;
10. Patients who are undergoing treatment of immunosuppressive drugs or long-term administration of immunosuppressive drugs after organ transplantation;
11. Patients with active infection or fever;
12. Subjects with severe cardiovascular and cerebrovascular diseases, diabetes and renal dysfunction;
13. Subjects with pregnancy or during the lactating period.
Clareo Health | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells
